Category - Developments

Developments

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing that Telomir-1 prevented cellular aging in patient-derived cells from children with progeria—Hutchinson-Gilford Progeria Syndrome (HGPS)—an...

June 18, 2025

Developments

MAIA enters into agreement with Roche to investigate THIO with Tecentriq

MAIA Biotechnology (NYSE American: MAIA) announced it has entered into a master supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to investigate the combination of MAIA’s telomere-targeting agent ateganosine...

June 18, 2025

Developments

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

Ekso Bionics Holdings (NASDAQ:EKSO) has announced that it has successfully demonstrated initial proof-of-concept in integrating new AI-enabled capabilities across its portfolio of Enterprise Health and Personal Health...

June 18, 2025

Developments

USPTO issues patent for Lipella’s diagnostic technology

Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing...

June 17, 2025

Developments

BioRestorative reports compelling early data for FDA-Fast-Tracked BRTX-100 for cLDD

BioRestorative Therapies (NASDAQ: BRTX) announced the presentation of promising preliminary blinded data from the first 36 subjects in its ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for...

June 13, 2025

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Developments

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that the first commercial benign prostatic hyperplasia (BPH) treatment utilizing the TULSA-PRO system’s new TULSA-AI Volume Reduction Module was successfully conducted...

June 10, 2025

Developments

Citius and Cardinal sign distribution agreement

Citius Oncology (NASDAQ: CTOR) announced it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH). According to Citius, the agreement is designed to help provide access to LYMPHIR, an...

June 9, 2025

Developments

Leef acquires New York License

Leef Brands (CSE: LEEF; OTCQB: LEEEF) announced it has officially closed on the acquisition of a Type 1 Cannabis Processor License in New York, enabling the company to engage in extraction, blending, infusion...

June 9, 2025

Category - Developments

Subscribe